Olympus Europa SE & Co. Kg (Olympus) has announced the commercial launch of the first three applications within its Olysense CAD/AI portfolio. The suite of cloud-based, integrated adaptive apps and solutions available in the first selected European countries is designed to address clinical and operational performance.
Olympus says the launch is the first step towards creating an ecosystem of intelligent endoscopy. The OlySense CAD/AI portfolio allows healthcare professionals to leverage the power of artificial intelligence (AI) with the aim of detecting and characterizing suspected tissues and lesions.
Healthcare is evolving. Gastroenterologists today face increasing challenges, including increased workloads, administrative burdens, budget constraints, and staff shortages. At the same time, the need for endoscopic surgery is increasing in light of demographic trends and ubiquitous lower and upper gastrointestinal conditions.
Efficient screening, early diagnosis, and appropriate treatment are essential for patient outcomes. Data-driven and AI-based solutions are designed to address these demands. So, Olympus has introduced OlySense to seamlessly integrate these advanced digital technologies with endoscopic devices.
“Since developing the world's first gastroscopy more than 70 years ago, Olympus has been committed to addressing the evolving needs of both healthcare providers and patients in the field of endoscopy,” General Manager of Olympus' Endoscopic Solutions Ecosystem. “Starting an intelligent endoscope ecosystem that connects software, hardware and services across the entire endoscopic care pathway is the next step in this journey.”
At launch, the Olysense CAD/AI software application portfolio includes three separate cloud-based AI support apps designed to assist healthcare professionals in the early diagnosis of lower GI disease during endoscopic procedures: Caddy, Cadu, and Smartibd. These three advanced medical device software products received European CE approval under the Medical Device Regulation (MDR) last year and are currently available in the region.
Caddy, a cloud-based AI for colonoscopy, supports potential signs of gastroenterologists and early signs of colorectal cancer in the detection and characterization of suspicious polyps. Instant image analysis on endoscopy, which supports endoscopic monitors, trained with a robust dataset to identify potential colorectal lesions in colonoscopy video frames, provides instant image analysis in endoscopic monitoring as you make informed decisions in real time. With Caddy, Olympus aims to have a positive impact on the prevention and early detection of colorectal cancer by showing an absolute increase in adenoma detection rate (ADR) of 7.4% compared to standard care.
Multicenter randomized controlled trials conducted in eight European hospitals demonstrated the potential for difficult and risky polyp techniques. When caddy was utilized in the above trials, endoscopicists achieved a relative increase of 136% for large polyps detected and 93% for large adenomas detected. Additionally, they detected 2.3 times the cellular serrated lesions (SSL), the most common precancerous serrated polyps, and the most common precancerous polyps, and up to 57% more flat adenomas, compared to when no AI systems were used during the procedure.
“Cloud-based and AI-powered endoscopic solutions are transforming clinical practice. By enabling real-time decision support and standardized assessment, clinicians can diagnose more accurately and more accurately, streamline workflows, and improve patient outcomes.” “Cloud-based endoscopic examinations open the door for ongoing innovation and wider access to advanced care.”
Caddy contributes to the detection and characterization of colorectal polyps, but the second AI-powered application, Cadu, addresses another gastrointestinal condition known as Barrett's esophagus. It aims to support healthcare professionals in accurate clinical decision-making by highlighting areas where there is most likely dysplasia in endoscopic images.
Finally, the third algorithm, SMARTIBD, supports the analysis of ulcerative colitis along Mayo scoring. Three applications support the diverse functions of Orisense CAD/AI within the endoscopic unit, contributing to improved outcomes in patients with various disease states.
In the future, ecosystem applications and products will continue to evolve, complementing AI-powered clinical solutions with seamless data connectivity across GI units and integration with hospital systems, facilitating clinical and operational efficiency and simplicity.
“The commercial launch of the Olysense CAD/AI application marks an exciting milestone as it introduces the first components of the intelligent endoscope ecosystem and provides customers with innovative cloud-based solutions that improve clinical performance,” Olympus EMEA's Medical Endoscopy Group.
